The latest international development is the signed Memorandum of Understanding between Abomics and Marand.
Marand is a globally operating Slovenian company, founded in 1991, that constantly challenges existing state of IT solutions in healthcare. Marand's goal is to improve patient safety, prevent errors, optimize workflows, and move towards fully digital patient care, based on decades of experience working with medical teams and developing healthcare IT products and solutions.
This is where Abomics steps is. The core function of Abomics is to improve patient lives by utilizing genetic data within clinical practice. By leveraging the knowledge acquired from human genome in order to increase the safety and efficacy medical treatments and medication. Pharmacogenetics will be the associative factor between the two companies.
Marand and Abomics have now committed to start collaboration to explore the potentials of more comprehensive decision support for clinicians in Marand's OPENeP medication module. With the integration of the GeneRx database of Abomics into Marand's medication module, clinicians could easily get an alert when they are prescribing drugs where checking patient genotype would be necessary and/or beneficial. The first clinical application area is planned to be mental health.
ln the future the two companies are willing to explore how to further expand business collaboration, first in the European countries and Russia, including new clinical segments.
The release is free for publication immediately.
© Koodiviidakko Oy - Y-tunnus 1939962-1